

2. (Amended) A synergistic therapeutic pharmaceutical composition for solid tumors comprising an effective amount of CPT-11 in combination with an effective amount of a topoisomerase II inhibitor, wherein said composition provides a synergistic effect in the treatment of solid tumors.

11. (Amended) A synergistic therapeutic pharmaceutical composition for solid tumors comprising an effective amount of at least two agents, wherein a first agent is CPT-11 and a second agent is doxorubicin, wherein said composition provides a synergistic effect in the treatment of solid tumors.

13. (Amended) A method of treating a solid tumor, comprising administering an effective amount of camptothecin, or a camptothecin derivative, as a first agent, in combination with an effective amount of a topoisomerase II inhibitor as a second agent, wherein the agents are administered simultaneously, semi-simultaneously, or separately, and wherein said first and second agents provide a synergistic effect in the treatment of said solid tumor.

REMARKS

By this Amendment, claims 1, 2, 11, and 13 are amended. Support for the amendments to claims 1, 2, 11, and 13 come from the specification as originally filed, at page 2, second paragraph, and page 6, first full paragraph, for example. Accordingly, no new matter is added by this Amendment. Currently, claims 1-20 are pending and under examination in this application.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com